培美曲塞联合顺铂或卡铂治疗晚期非小细胞肺癌的临床观察  

Pemetrexed plus Cisplatin or Carboplatin in the Treatment of Patients with Non-small Cell Lung Cancer

作　　者：崔艳艳[1] 綦会霞[1] 霍山 

机构地区：[1]赤峰学院附属医院肿瘤内科,内蒙古赤峰024000 [2]赤峰市220医院放射科,内蒙古赤峰024000

出　　处：《肿瘤基础与临床》2014年第6期487-488,共2页journal of basic and clinical oncology

摘　　要：目的分析培美曲塞联合顺铂或卡铂治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法41例晚期NSCLC患者接受培美曲塞联合顺铂或卡铂治疗方案。结果 41例晚期NSCLC患者中,有效率为26.8%(11/41),疾病控制率为63.4%(26/41);治疗后有25例患者(61.0%)KPS评分提高;毒副反应主要为骨髓抑制和胃肠道反应。结论培美曲塞联合顺铂或卡铂治疗晚期NSCLC安全有效。Objective To evaluate the efficacy and toxicities of pemetrexed plus cisplatin or carboplatin in the treatment of patients with advanced non-small cell lung cancer（ NSCLC）. Methods Forty-one patients with ad-vanced NSCLC received pemetrexed plus cisplatin or carboplatin. Results Among the 41 patients advanced NSCLC,the response rate was 26. 8%（11/41）,the disease control rate was 63. 4%（26/41）;the KPS scores in the 25 patients（61. 0%）were increased. The common toxicities were bone marrow depression and gastrointestinal reaction. Conclusion Pemetrexed plus cisplatin or carboplatin is a safe and effective regimen for the patients with advanced NSCLC.

关 键 词：非小细胞肺癌 培美曲塞 顺铂 卡铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]